If the CMO does not respond to the first-line therapy, various other treatment options have been explored and appear to show benefits, such as periocular TCA, intravitreal steroid, and intravitreal anti-VEGF agents. The gene discussed is VEGFA; the disease is chronic recurrent multifocal osteomyelitis.